Literature DB >> 7598461

Treatment of osteoporosis.

K M Prestwood1, C C Pilbeam, L G Raisz.   

Abstract

Osteoporosis is a common disorder affecting the health of many adults. Strategies for fracture prevention include optimization of peak bone mass and prevention of bone loss at menopause and with aging. Genetic, nutritional, and life-style factors influence peak bone mass and may be used to focus preventive efforts. Once peak bone mass is reached, increased bone resorption may be the major pathogenetic factor. Calcium plus vitamin D, estrogen replacement therapy, calcitonin, and etidronate are agents currently available for treatment of osteoporosis; they act by inhibiting bone resorption. The failure of bone formation to keep pace with bone resorption also contributes to bone loss. Fluoride and intermittent parathyroid hormone therapy increase bone formation; however, more data are needed to determine efficacy. Insulin-like growth factors, transforming growth factor-beta (TGF-beta), and bone morphogenetic proteins may stimulate bone formation, but they have not yet been tested clinically. New approaches to treatment of osteoporosis will emerge as our understanding of the pathogenesis increases.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7598461     DOI: 10.1146/annurev.med.46.1.249

Source DB:  PubMed          Journal:  Annu Rev Med        ISSN: 0066-4219            Impact factor:   13.739


  13 in total

1.  Synthesis and Reactivity Studies of α,α-Difluoromethylphosphinates.

Authors:  Isabelle Abrunhosa-Thomas; Laëtitia Coudray; Jean-Luc Montchamp
Journal:  Tetrahedron       Date:  2010-06-19       Impact factor: 2.457

2.  Neohesperidin promotes the osteogenic differentiation of bone mesenchymal stem cells by activating the Wnt/β-catenin signaling pathway.

Authors:  Yue-Wen Chang; Wen-Jun Zhu; Wei Gu; Jun Sun; Zhi-Qiang Li; Xiao-En Wei
Journal:  J Orthop Surg Res       Date:  2021-05-21       Impact factor: 2.359

3.  Radical reaction of sodium hypophosphite with terminal alkynes: synthesis of 1,1-bis-H-phosphinates.

Authors:  Sonia Gouault-Bironneau; Sylvine Deprèle; Amber Sutor; Jean-Luc Montchamp
Journal:  Org Lett       Date:  2005-12-22       Impact factor: 6.005

4.  Fasudil Ameliorates Osteoporosis Following Myocardial Infarction by Regulating Cardiac Calcitonin Secretion.

Authors:  Chengyu Xiang; Yeqian Zhu; Maohua Xu; Dingguo Zhang
Journal:  J Cardiovasc Transl Res       Date:  2022-05-12       Impact factor: 4.132

Review 5.  Bone-Targeted Nanoparticle Drug Delivery System: An Emerging Strategy for Bone-Related Disease.

Authors:  Yulin Chen; Xianmin Wu; Jiadong Li; Yingying Jiang; Ke Xu; Jiacan Su
Journal:  Front Pharmacol       Date:  2022-05-31       Impact factor: 5.988

6.  Vericiguat Modulates Osteoclast Differentiation and Bone Resorption via a Balance between VASP and NF-κB Pathways.

Authors:  Kaiqiang Sun; Fanqi Kong; Feng Lin; Fudong Li; Jingchuan Sun; Changzhen Ren; Bing Zheng; Jiangang Shi
Journal:  Mediators Inflamm       Date:  2022-06-16       Impact factor: 4.529

7.  Fat's loss is bone's gain.

Authors:  Liming Pei; Peter Tontonoz
Journal:  J Clin Invest       Date:  2004-03       Impact factor: 14.808

Review 8.  An Insight into the Effect of Exercises on the Prevention of Osteoporosis and Associated Fractures in High-risk Individuals.

Authors:  Helen Senderovich; Andrew Kosmopoulos
Journal:  Rambam Maimonides Med J       Date:  2018-01-29

Review 9.  Role of LncRNAs and CircRNAs in Bone Metabolism and Osteoporosis.

Authors:  Suryaji Patil; Kai Dang; Xin Zhao; Yongguang Gao; Airong Qian
Journal:  Front Genet       Date:  2020-11-13       Impact factor: 4.599

Review 10.  The Effects of Selenium on Bone Health: From Element to Therapeutics.

Authors:  Taeyoung Yang; So-Young Lee; Kyung-Chae Park; Sin-Hyung Park; Jaiwoo Chung; Soonchul Lee
Journal:  Molecules       Date:  2022-01-08       Impact factor: 4.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.